Acura Pharmaceuticals Inc. (ACUR) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS
Acura Pharmaceuticals Inc. (NASDAQ:ACUR) released its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($0.19) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.08. Acura Pharmaceuticals had a negative net margin of 303.77% and a negative return on equity of 178.04%.
Shares of Acura Pharmaceuticals (NASDAQ:ACUR) opened at 1.03 on Tuesday. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $1.82. Acura Pharmaceuticals has a 52 week low of $0.86 and a 52 week high of $3.52. The firm’s market capitalization is $12.19 million.
ACUR has been the topic of several research reports. Roth Capital set a $6.00 price target on shares of Acura Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 18th. FBR & Co reiterated an “outperform” rating and set a $10.00 price objective on shares of Acura Pharmaceuticals in a research note on Friday, October 21st. Finally, Zacks Investment Research downgraded shares of Acura Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 1st.
About Acura Pharmaceuticals
Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.
Receive News & Stock Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.